


SCARD Pool report for 01-01-2021 to 31-12-2021

| Participants | Doctors Patients | 318 65.677 | |
|--------------|-----------------------------|---------------|---------|
| | rations | 05,077 | |
| Specimens | New lesions | 121,836 | 84.56% |
| | Previously biopsied lesions | 22,251 | 15.44% |
| | Total lesions | 144,087 | 100.00% |

Breakdown of new versus previously biopsied specimens



| Percentage of new lesions tested which were malignant | 63.95% |
|--|--------|
| Percentage of Definitively excised lesions that were malignant | 81.36% |
| Lesions tested to find one melanoma (NNT) | 3.76 |
| Percentage of lesions tested for NMSC which were NMSC | 78.63% |
| Ratio of New BCCs : New Melanomas | 9:1 |

Accuracy

Diagnostic sensitivity

| Melanomas | 76.53% of 4,316 |
|-----------|------------------|
| All NMSC | 96.06% of 70,721 |
| BCCs | 91.79% of 37,914 |
| SCCs | 82.57% of 32,500 |
| | |

Positive predictive value

| Melanomas | 43.95% of 7,516 |
|-----------|------------------|
| All NMSC | 84.67% of 80,235 |
| BCCs | 43.38% of 80,235 |
| SCCs | 67.88% of 39,529 |

Adequacy


Percentage of definitively managed malignant cases where surgical margins were adequate

| BCC | 88.07% of 25,870 |
|---------------------------|------------------|
| IEC/Bowens disease | 80.85% of 8,863 |
| SCC | 86.52% of 8,992 |
| Keratoacanthoma | 90.59% of 1,073 |
| Melanoma - in situ | 76.33% of 2,915 |
| Melanoma - invasive | 70.24% of 662 |
| Melanoma - invasive > 1mm | 42.06% of 107 |
| Other malignant | 69.05% of 126 |



Lesion Breakdown Histological Diagnosis

| BCC (unspecified type) | | 0.07% |
|-----------------------------|--------|--------|
| BCC - Superficial | 11,644 | 9.54% |
| BCC - Nodular/Solid | 21,702 | 17.79% |
| BCC - Aggressive | 4,488 | 3.68% |
| IEC/Bowens disease | 18,386 | 15.07% |
| SCC | 12,585 | 10.32% |
| Keratoacanthoma | 1,529 | 1.25% |
| Pinkus Fibroepithelioma | 19 | 0.02% |
| Merkel cell tumour | 17 | 0.01% |
| Other malignant | 171 | 0.14% |
| NMSC Metastasis | 5 | 0.00% |
| Melanoma - in situ | 3,212 | 2.63% |
| Melanoma - invasive | 837 | 0.69% |
| Melanoma - invasive > 1mm | 233 | 0.19% |
| Melanoma - metastasis | 34 | 0.03% |
| MELTUMP | 95 | 0.08% |
| Naevus - other | 7,258 | 5.95% |
| Naevus - dysplastic/Clark | 3,579 | 2.93% |
| Naevus - blue | 439 | 0.36% |
| Naevus - Spitz/Reed | 171 | 0.14% |
| Naevus - Compound | 58 | 0.05% |
| Solar keratosis | 10,353 | 8.49% |
| Solar lentigo | 1,489 | 1.22% |
| Seborrhoeic keratosis | 5,691 | 4.66% |
| Lentigo Simplex | 2 | 0.00% |
| Lichenoid keratosis (LPLK) | 2,125 | 1.74% |
| Dermatofibroma | 885 | 0.73% |
| Sebaceous gland hyperplasia | 276 | 0.23% |
| Benign cyst | 1,957 | 1.60% |
| Other benign | 7,846 | 6.43% |
| Histology Pending | 168 | 0.14% |





Procedures

| Deminitive Surgical Managen | ient useu to exclude melanoma | | |
|-----------------------------|--|--------|--------|
| | Ellipse | 3,387 | 86.87% |
| | Flap | 51 | 1.31% |
| | Graft - SSG | 0 | 0% |
| | Graft - FTSG | 8 | 0.21% |
| | No Closure | 9 | 0.23% |
| | Shave/Saucerisation | 35 | 0.90% |
| | Curettage & Cautery | 38 | 0.97% |
| | Liquid N2 freeze/thaw | 2 | 0.05% |
| | PDT | 0 | 0% |
| | Imiquimod | 0 | 0% |
| | 5 FU cream | 0 | 0% |
| | GP referral | 228 | 5.85% |
| | Specialist referral | 126 | 3.23% |
| | Other | 3 | 0.08% |
| Biopsy used to exclude mela | | | |
| | Punch - sample | 697 | 5.35% |
| | Shave - sample | 1,598 | 12.27% |
| | Incisional | 232 | 1.78% |
| | Punch - removal | 2,599 | 19.96% |
| | Shave - removal | 2,520 | 19.35% |
| | Excisional | 5,296 | 40.66% |
| | Curettage | 20 | 0.15% |
| | Other | 58 | 0.45% |
| Breakdown of definitive mar | nagement procedures for malignant conditions | | |
| | Ellipse | 41,628 | 63.51% |
| | Flap | 5,408 | 8.25% |
| | Graft - SSG | 289 | 0.44% |
| | Graft - FTSG | 1,530 | 2.33% |
| | No Closure | 218 | 0.33% |
| | Shave/Saucerisation | 1,045 | 1.59% |
| | Curettage & Cautery | 8,537 | 13.02% |
| | Liquid N2 freeze/thaw | 564 | 0.86% |
| | PDT | 105 | 0.16% |
| | Imiquimod | 519 | 0.79% |
| | 5 FU cream | 1,309 | 2.00% |
| | GP referral | 1,338 | 2.04% |
| | Specialist referral | 2,244 | 3.42% |
| | Other | 171 | 0.26% |
| Breakdown of definitive mar | nagement procedures for benign conditions | | |
| | Ellipse | 5,618 | 78.08% |
| | Flap | 81 | 1.13% |
| | Graft - SSG | 5 | 0.07% |
| | Graft - FTSG | 14 | 0.19% |
| | No Closure | 31 | 0.43% |
| | Shave/Saucerisation | 277 | 3.85% |
| | Liquid N2 freeze/thaw | 106 | 1.47% |
| | 5 FU cream | 106 | 1.47% |
| | GP referral | 118 | 1.64% |
| | Specialist referral | 57 | 0.79% |
| | Other | 100 | 1.39% |
| | | | |



Procedures (continued)


Percentage of procedures/closures that were complex

| Complex Closures | 9.68% of 43,255 |
|--|-----------------|
| Complex Closures (inc Curettage & Cautery) | 8.62% of 48,570 |

Locations

Breakdown of melanomas by location and percentage melanomas of total lesions at that location

| , | | |
|---------------|------|-----------------|
| Nose | 46 | 0.63% of 7,351 |
| Lip | 5 | 0.28% of 1,818 |
| Ear | 100 | 1.80% of 5,544 |
| Eyelid | 15 | 1.29% of 1,162 |
| Other face | 418 | 2.03% of 20,599 |
| Scalp | 115 | 2.26% of 5,080 |
| Neck | 197 | 3.13% of 6,295 |
| Shoulder | 315 | 5.60% of 5,620 |
| Chest | 210 | 2.95% of 7,108 |
| Abdomen | 95 | 6.13% of 1,549 |
| Genitalia | 2 | 0.96% of 209 |
| Back | 1360 | 7.88% of 17,267 |
| Buttock | 15 | 5.68% of 264 |
| Arm | 460 | 6.30% of 7,299 |
| Forearm | 272 | 3.06% of 8,880 |
| Hand Dorsal | 8 | 0.17% of 4,696 |
| Hand Palmar | 0 | 0% of 29 |
| Finger Dorsal | 3 | 0.38% of 787 |
| Finger Nail | 0 | 0% of 18 |
| Finger Palmar | 0 | 0% of 11 |
| Thigh | 179 | 4.89% of 3,660 |
| Leg | 454 | 3.07% of 14,772 |
| Foot Dorsal | 35 | 3.07% of 1,139 |
| Foot Plantar | 3 | 2.94% of 102 |
| Toe Dorsal | 4 | 1.97% of 203 |
| Toe Nail | 0 | 0% of 15 |
| Toe Plantar | 1 | 9.09% of 11 |
| Palm Or Sole | 0 | 0% of 0 |
| | | |



Upper Limbs - 17.23%